dc.contributor.author | Harris, Patrick N. A. | |
dc.contributor.author | Tambyah, Paul Anatharajah | |
dc.contributor.author | Lye, David Chien | |
dc.contributor.author | Mo Yinli | |
dc.contributor.author | Lee, Tau Hong | |
dc.contributor.author | Yılmaz, Mesut | |
dc.contributor.author | Alenazi, Tamer H. | |
dc.contributor.author | Arabi, Yaseen | |
dc.contributor.author | Falcone, Marco | |
dc.contributor.author | Bassetti, Matteo | |
dc.contributor.author | Righi, Elda | |
dc.contributor.author | Rogers, Benjamin A. | |
dc.contributor.author | Kanj, Souha | |
dc.contributor.author | Bhally, Hasan | |
dc.contributor.author | Iredell, Jon | |
dc.contributor.author | Mendelson, Marc | |
dc.contributor.author | Boyles, Tom H. | |
dc.contributor.author | Looke, David | |
dc.contributor.author | Miyakis, Spiros | |
dc.contributor.author | Walls, Genevieve | |
dc.contributor.author | Al Khamis, Mohammed | |
dc.contributor.author | Zikri, Ahmed | |
dc.contributor.author | Crowe, Amy | |
dc.contributor.author | Ingram, Paul | |
dc.contributor.author | Daneman, Nick | |
dc.contributor.author | Griffin, Paul | |
dc.contributor.author | Athan, Eugene | |
dc.contributor.author | Lorenc, Penelope | |
dc.contributor.author | Baker, Peter | |
dc.contributor.author | Roberts, Leah | |
dc.contributor.author | Beatson, Scott A. | |
dc.contributor.author | Peleg, Anton Y. | |
dc.contributor.author | Harris-Brown, Tiffany | |
dc.contributor.author | Paterson, David L. | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:50:11Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:50:11Z | |
dc.date.issued | 2018 | en_US |
dc.identifier.citation | Harris, P., Tambyah, P., Lye, D, Mo, Y., Lee, T., Yılmaz, M. ... Paterson, D. L. (2018). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance a randomized clinical trial. Jama-Journal of the American Medical Association, 320(10), 984-994. https://dx.doi.org/10.1001/jama.2018.12163 | en_US |
dc.identifier.issn | 0098-7484 | |
dc.identifier.issn | 1538-3598 | |
dc.identifier.uri | https://dx.doi.org/10.1001/jama.2018.12163 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/1907 | |
dc.description | WOS: 000444341400012 | en_US |
dc.description | PubMed ID: 30208454 | en_US |
dc.description.abstract | IMPORTANCE Extended-spectrum beta-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum beta-lactamase producers. OBJECTIVES To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. DESIGN, SETTING, AND PARTICIPANTS Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. INTERVENTIONS Patients were randomly assigned 1: 1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. RESULTS Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6%[1-sided 97.5% CI, -infinity to 14.5%]; P = .90 for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group. CONCLUSIONS AND RELEVANCE Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting. | en_US |
dc.description.sponsorship | University of Queensland; Australian Society for Antimicrobials (ASA); International Society for Chemotherapy (ISC); National University Hospital Singapore Clinician Researcher Grant [NUHSRO/2014/121/CRG/07]; Australian Infectious Disease Centre; Australian Genome Research Facility; Royal College of Pathologists of Australasia (RCPA) Foundation; Study, Education, and Research Committee (SERC) of Pathology Queensland; National Health and Medical Research Council (NHMRC) Career Development Fellowship; Australian Postgraduate Award from the University of Queensland; NHMRC Career Development and Practitioner Fellowship; NHMRC Practitioner Fellowship | en_US |
dc.description.sponsorship | The study was sponsored by the University of Queensland. This study was funded by grants from the Australian Society for Antimicrobials (ASA), International Society for Chemotherapy (ISC), National University Hospital Singapore Clinician Researcher Grant NUHSRO/2014/121/CRG/07. Whole-genome sequencing was funded by grants from the Australian Infectious Disease Centre and Australian Genome Research Facility; the Royal College of Pathologists of Australasia (RCPA) Foundation; and the Study, Education, and Research Committee (SERC) of Pathology Queensland. Dr Beatson was supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship during the course of the trial. Dr Harris was supported by an Australian Postgraduate Award from the University of Queensland. Dr Peleg was supported by a NHMRC Career Development and Practitioner Fellowship during the course of the trial. Dr Paterson was supported by a NHMRC Practitioner Fellowship during the course of the trial. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Medical Association | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Beta-Lactamases | en_US |
dc.subject | Escherichia Coli | en_US |
dc.subject | ESBL Genes | en_US |
dc.subject | Ceftriaxone | en_US |
dc.subject | Meropenem | en_US |
dc.subject | Piperacillin Plus Tazobactam | en_US |
dc.title | Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance a randomized clinical trial | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Jama-Journal of the American Medical Association | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-8022-7325 | en_US |
dc.identifier.volume | 320 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | 984 | en_US |
dc.identifier.endpage | 994 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1001/jama.2018.12163 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.scopusquality | Q1 | en_US |